Optimum PSA reflex-range.
OBJECTIVE
Aim of this study was to evaluate different decision strategies based on variations in the cut-off value of percent free PSA and in the range of total PSA values (reflex range) in which free PSA testing was applied. We compared these strategies to conventional total PSA testing by determining which strategies would provide a maximum decrease in unnecessary biopsies with a minimum number of additional undetected cancers.


METHODS
This retrospective study was conducted with 807 patients who were referred to transrectal ultrasound biopsies for elevated serum PSA levels or for abnormal digital rectal examination. Overall 156 patients were affected by primary prostate cancer (CaP), 651 were controls without prostate cancer (benign prostatic hypertrophy, prostatic intraepithelial neoplasm, prostatitis or normal prostatic gland).


RESULTS
Total PSA was significantly higher (F=4.93; p<0.0001) and percent free PSA was significantly lower in cancer patients than in controls (F=2.16; p<0.0001). Sensitivity, specificity and the positive likelihood ratio (LR+) of PSA and percent free PSA have been calculated for several total PSA intervals: PSA 4-10 ng/ml, 3-10 ng/ml, 3-20 ng/ml, 2-10 ng/ml, 2-20 ng/ml. These data suggest that in the reflex range 2-10 ng/ml there are the best results. On ROC comparison restricted to men with total PSA between 2 and 10 ng/ml, percent free PSA also had a higher area under the curve than total PSA (AUC 0.7452 for free percent PSA; 0.6267 for total PSA: p = 0.0059).


CONCLUSIONS
The PSA revolution that occurred over the previous 2 decades has positively impacted the detection of prostate cancer. Percent free PSA improves specificity, at the beginning the percent free PSA was used only in the gray zone 4-10 ng/ml. Analyzing our data, we confirm that the usefulness of percent free PSA in prostate cancer diagnosis increases, enlarging the reflex range. Our best result is obtained in the reflex range 2-10 ng/ml using a percent free PSA cut-off of 22%.
Benecchi
Luigi
L
Division of Urology, Fidenza Hospital, Parma, Italy. benecchi.luigi@libero.it
D000368:Aged; D001706:Biopsy; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis; D019048:Prostatic Intraepithelial Neoplasia / Q000097:blood / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D011472:Prostatitis / Q000097:blood / Q000175:diagnosis; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
D017430:Prostate-Specific Antigen